<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276428</url>
  </required_header>
  <id_info>
    <org_study_id>16983</org_study_id>
    <secondary_id>I8H-JE-BDCK</secondary_id>
    <nct_id>NCT04276428</nct_id>
  </id_info>
  <brief_title>A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Multiple-Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 in Japanese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of a study drug known as LY3209590
      in Japanese participants with type 2 diabetes. Side effects and tolerability will be
      documented. Blood samples will be taken to compare how the body handles the drug and how it
      affects blood sugar levels. The study will last almost five months for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">December 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Drug-Plasma-Concentration-Versus-Time Curve from Time Zero to 168 Hours Postdose (AUC[0-168]) of LY3209590</measure>
    <time_frame>Predose on Day 1 through Day 85</time_frame>
    <description>PK: AUC(0-168) of LY3209590</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>PD: Change from Baseline in Fasting Plasma Glucose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3209590</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Degludec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin degludec administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3209590</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3209590</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Insulin Degludec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes mellitus (T2DM) for at least 1 year

          -  Have received a stable daily dose of basal insulin at screening

          -  Have hemoglobin A1c (HbA1c) greater than or equal to (≥)6.5 percent (%) and less than
             or equal to (≤)10.0% at screening

          -  Have a body mass index greater than (&gt;)18.5 and ≤40.0 kilograms per square meter
             (kg/m²) at screening

        Exclusion Criteria:

          -  Have received a total daily dose of insulin &gt;1.2 units per kilogram (U/kg) of body
             weight at screening

          -  Have received insulins except for basal insulins

          -  Have received sulfonylurea at more than half of the maximum approved dose level

          -  Have a history of multiple and/or severe allergies to drugs or foods or a history of
             severe anaphylactic reaction or history of significant atopy

          -  Have had more than 1 episode of severe hypoglycemia within 6 months before entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81457228655</phone>
    </contact>
    <investigator>
      <last_name>Keitoku Matsumoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P-one clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81426255216</phone>
    </contact>
    <investigator>
      <last_name>Kenichi Furihata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hospital, Tokyo</name>
      <address>
        <city>Shinjyuku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81 3 3355 7200</phone>
    </contact>
    <investigator>
      <last_name>Koichi Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

